What's new

Human medicines European public assessment report (EPAR): Mycapssa, octreotide, Date of authorisation: 02/12/2022, Status: Withdrawn

Human medicines European public assessment report (EPAR): Mycapssa, octreotide, Date of authorisation: 02/12/2022, Status: Withdrawn

Mar 21, 2025 - 11:33
 0
Human medicines European public assessment report (EPAR): Mycapssa, octreotide, Date of authorisation: 02/12/2022, Status: Withdrawn
Human medicines European public assessment report (EPAR): Mycapssa, octreotide, Date of authorisation: 02/12/2022, Status: Withdrawn
Read More

Tags:

Previous Article

Orphan designation: Octreotide acetate Treatment of acromegaly, 05/08/2013 Withd...

Next Article

BIPOC-owned beauty brands face a new reality in the post-DEI era

Related Posts

Opinion/decision on a Paediatric investigation plan (PIP): Rinvoq, Upadacitinib, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Immune system disorders, PIP number: P/0010/2024

Opinion/decision on a Paediatric investigation plan (PI...

Mar 13, 2025  0

Human medicines European public assessment report (EPAR): Avamys, fluticasone furoate, Date of authorisation: 11/01/2008, Revision: 24, Status: Authorised

Human medicines European public assessment report (EPAR...

Feb 18, 2025  0

Human medicines European public assessment report (EPAR): Holoclar, ex vivo expanded autologous human corneal epithelial cells containing stem cells, Date of authorisation: 17/02/2015, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR...

Mar 7, 2025  0